https://www.avient.com/sites/default/files/2023-11/Renol Fiber Colorants Deep Black Product Bulletin.pdf
Textile products that undergo frequent washing also require additional attributes such as enhanced processability and superior washing fastness.
https://www.avient.com/sites/default/files/2021-12/avient-investor-day-registration-details21.pdf
In addition, the company will provide an update on the integration of the Clariant Color business, including future synergy capture, and a financial overview.
https://www.avient.com/sites/default/files/2021-06/fl.datasheet-pultrusion.pdf
Key Features • .25mm – 5.00mm sizes available • Round, oval, rectangular shapes available • Swellcoat® water blocking SAP available • Additional up jacketing up to 17mm • Dielectric Strength Members (exception of carbon) • Rod printing available for accurate length reading FIBER-LINE® FIBERS SUITABLE FOR PULTRUSION • Kevlar® Para-Aramid • Vectran® LCP • Zylon® PBO • Carbon Fiber • Fiberglass FIBER-LINE® PRODUCTS ADDED BY PULTRUSION • Strength elements • Central Strength Members • Tracer Wire PULTRUSION FIBERS PROCESSES PRODUCTS Overview FIBER-LINE® pultrusion is the process of impregnating and curing fibers in a resin system to form a rigid rod.
https://www.avient.com/knowledge-base/article/injection-molding-mold-design
For spiral flow information about a specific grade or additional details about the spiral flow test procedure, please refer to the TPE Tip #7.
In addition, the sprue will need to be trimmed thus appearance quality of the part is usually poor.
https://www.avient.com/industries/packaging/industrial-packaging/surface-protection
Microbial susceptibility of various polymers and evaluation of thermoplastic elastomers with antimicrobial additives
Examine the technical details of our research study to test against microbial attack, including the efficacy of GLS™ TPES with antimicrobial additives
https://www.avient.com/sites/default/files/2022-11/AVNT Q3 2022 Earnings Presentation - Website Final.pdf
Sales EBITDA Specialty Engineered Materials Color Additives and Inks $585M$3,635M (1) Transportation 9% Healthcare 8% 23 C O L O R , A D D I T I V E S & I N K S 2022 REVENUE | $2 .3 B ILL ION US & Canada 35% EMEA 40% Asia 20% Latin America 5% END MARKET REGION 24 Packaging 33% Consumer 22% Healthcare 9% Industrial 15% Transportation 8% Building & Construction 11% Telecommunications 1% Energy 1% Figures represent 2022 full year estimates S P E C I A LT Y E N G I N E E R E D M AT E R I A L S 2022 PRO FORMA REVENUE | $1 .3 B ILL ION END MARKET US & Canada 50% EMEA 35% Asia 15% REGION 25 Figures represent 2022 full year estimates Packaging 5% Consumer 19% Healthcare 8%Industrial 16% Transportation 10% Telecommunications 10% Energy 9% Defense 15% Building & Construction 8% Packaging 31% Consumer 28% Healthcare 8% Industrial 13% Building & Construction 5% Telecommunications 3% Energy 2% Defense 1% Asia (20% of sales) Transportation 9% 2022 PROFORMA AVIENT REGIONAL SALES BY END MARKET Packaging 29% Consumer 13% Healthcare 5% Industrial 17% Building & Construction 11% Energy 5% Defense 7% EMEA (35% of sales) Transportation 10% Packaging 14% Consumer 23% Healthcare 11% Industrial 15% Building & Construction 12% Energy 5% Defense 7% US & Canada (40% of sales) Transportation 7% Packaging 49% Consumer 22% Healthcare 8% Industrial 9% Building & Construction 6% Telecommunications 1% LATAM (5% of sales) Transportation 5% Telecommunications 3%Telecommunications 6% Figures represent 2022 full year estimates Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.
In addition, operating income before the effect of special items is a component of Avient’s annual and long-term employee incentive plans and is used in debt covenant computations.
Three Months Ended September 30, 2022 Three Months Ended September 30, 2021 Reconciliation to Condensed Consolidated Statements of Income $ EPS $ EPS Net (loss) income from continuing operations attributable to Avient shareholders $ (27.4) $ (0.30) $ 33.7 $ 0.37 Special items, after tax (Attachment 3) 68.3 0.75 11.7 0.13 Amortization expense, after-tax 13.4 0.14 $ 11.0 $ 0.11 Adjusted net income / EPS $ 54.3 $ 0.59 $ 56.4 $ 0.61 2009* 2012* 2015 2018 Net income from continuing operations attributable to Avient common shareholders $ 106.7 $ 53.3 $ 144.6 $ 161.1 Joint venture equity earnings, after tax (19.0) — — — Special items, before tax (48.7) 55.1 87.6 59.5 Special items, tax adjustments (27.2) (18.9) (58.7) (25.3) Amortization expense, after tax 1.8 8.3 10.4 19.5 Adjusted net income from continuing operations attributable to Avient common shareholders $ 13.6 $ 97.8 $ 183.9 $ 214.8 Diluted shares 93.4 89.8 88.7 80.4 Adjusted EPS attributable to Avient common shareholders $ 0.15 $ 1.09 $ 2.08 $ 2.67 * Historical results have been updated to reflect subsequent changes to accounting principle and discontinued operations, excluding any changes as a result of discontinued operations from the sale of the Designed Structures and Solutions segment (DSS) and the Performance Products and Solutions segment (PP&S). 1 Year Ended December 31, Reconciliation to EBITDA and Adjusted EBITDA: 2006 2018 Sales $ 2,622.4 $ 3,533.4 Net income from continuing operations – GAAP $ 133.5 $ 160.8 Income tax expense 29.7 36.4 Interest expense 63.1 62.8 Depreciation and amortization 57.1 91.5 EBITDA $ 283.4 $ 351.5 Special items, before tax (34.0) 59.5 Depreciation and amortization included in special items — (3.0) JV - equity income (107.0) — Adjusted EBITDA $ 142.4 $ 408.0 EBITDA as a % of sales 5.4 % 11.5 % Reconciliation of Color, Additives and Inks EBITDA Q3 2022 Q3 2021 Operating Income 68.6 66.8 Depreciation and amortization 24.2 26.6 EBITDA 92.8 $ 93.4 Reconciliation of Specialty Engineered Materials EBITDA Q3 2022 Q3 2021 SEM(1) Pro forma APM(1) Pro forma SEM SEM Pro forma APM Pro forma SEM Operating Income 31.4 6.3 37.7 30.0 13.9 43.9 Depreciation and amortization 12.9 10.9 23.8 7.9 18.4 26.3 EBITDA $ 44.3 $ 17.2 $ 61.5 $ 37.9 $ 32.3 $ 70.2 Reconciliation of Specialty Engineered Pro Forma Sales Q3 2022 Q3 2021 Sales 258.2 231.7 Pro forma APM(1) 60.7 94.1 Pro forma sales $ 318.9 $ 325.8 Reconciliation of Avient Pro Forma Sales Q3 2022 Q3 2021 Sales 823.3 818.0 Pro forma APM(1) 60.7 94.1 Pro forma sales $ 884.0 $ 912.1 (1) - Q3 2022 SEM results reflect one month of APM’s results while owned by Avient, as the acquisition closed on September 1, 2022.
https://www.avient.com/sites/default/files/resources/TPE_Overmolding_Solutions_for_Engineering_Thermoplastics.pdf
In addition, they also have limitations when it comes to combining material of different chemistries.
In addition the diffusion and viscoelastic properties of the elastomer has an influence on the adhesion properties.
In addition selection of the overmold TPE depends on the end-use application and environment.
https://www.avient.com/sites/default/files/2022-08/Schedule 2 a_b_c - SCCs_0.pdf
In case of pseudonymisation, the additional information for attributing the personal data to a specific data subject shall, where possible, remain under the exclusive control of the data exporter.
In addition, the following terms have the following meanings: a.
In case of pseudonymisation, the additional information for attributing the personal data to a specific data subject shall, where possible, remain under the exclusive control of the data exporter.
https://www.avient.com/sites/default/files/2020-12/firecon-cpe-product-bulletin.pdf
The materials are compounded with fillers, flame- retardants, additives and stabilizers to provide a customized desired level of performance.
https://www.avient.com/sites/default/files/2022-08/Humotech Robotic Prosthetic Case Study.pdf
In addition to adjusting to a new way of life, amputees are often challenged with identifying and acquiring an appropriate prosthetic device.